Business
Block Listing Applications to AIM
Block Listing Applications to AIM.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n 1 February 2023\n \n \n \n \n \n \n \n \n Futura Medical plc\n \n \n \n \n (\"Futura\" or the \"Company\")\n \n \n \n \n Block Listing Applications to AIM\n \n \n \n \n \n \n \n \n \n Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces application has been made to AIM for a block listing of 4,444,942 ordinary shares of 0.2 pence each in the Company (\"Ordinary Shares\"). This will be used to facilitate the admission of shares to trading following the exercise of options granted under the Company's LTIP Scheme as announced on 12 January 2023.\n \n \n \n \n \n Additionally, an application has been made to the London Stock Exchange to extend the Company's existing block listings by a total of 1,100,000 Ordinary Shares which may arise pursuant to the exercise of options under the Company's EMI Share Option Scheme.\n \n \n \n \n \n The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company. Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.\n \n \n \n \n \n The block listing is expected to become effective on 2 February 2023. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.\n \n \n \n \n \n At the time of this announcement, the Company has 288,133,957 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 288,133,957 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n \n \n \n \n \n \n ENDS\n \n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \...